Is retatrutide better than semaglutide or tirzepatide?

The Phase 2 weight-loss numbers are eye-catching — up to 24.2% at 48 weeks — but these come from separate trials with different populations and designs. Head-to-head randomized comparisons are what would settle it, and retatrutide is still in Phase 3 development. Treat cross-trial comparisons as suggestive, not decided.

Can I buy retatrutide?

Not legitimately. It is investigational and only available inside clinical trials. Anything sold as 'retatrutide' by a research-chemical or gray-market vendor is not the trial drug, is not quality-controlled, and is not authorized for human use.

research

Retatrutide: What the Trials Actually Show

The triple-agonist everyone's whispering about has real, published human RCTs behind it — up to 24.2% weight loss at 48 weeks and dramatic liver-fat drops. Here's what the data say, and what it still can't tell you.

By LetsTalkPeps StaffJuly 5, 20262 min read● Human RCT evidence

Educational content only — this is not medical advice. Retatrutide is investigational and studied under medical supervision.

Most of the peptide internet runs on rat studies and vibes. Retatrutide is the rare exception worth taking seriously, because the loud claims about it trace back to actual randomized human trials — including one in the New England Journal of Medicine. So let's do the thing nobody else does and just read them.

What it is

Retatrutide (LY3437943) is a once-weekly injectable triple agonist: it activates the GIP, GLP-1, and glucagon receptors simultaneously. It extends the GLP-1 (semaglutide) and dual GIP/GLP-1 (tirzepatide) lineage by adding glucagon-receptor activity, which is thought to raise energy expenditure and hit liver fat. A Phase 1b trial in type 2 diabetes established a roughly 6-day half-life, which is what makes weekly dosing work.

The obesity trial

The headliner is the Phase 2 obesity trial (NEJM, 2023): 338 adults, double-blind, placebo-controlled, 48 weeks. Least-squares mean body-weight change came in at:

1 mg: −8.7%
4 mg: −17.1%
8 mg: −22.8%
12 mg: −24.2%
Placebo: −2.1%

Dose-dependent, and at the top dose, genuinely large. That −24.2% figure is the number driving all the hype — and unlike most peptide claims, it comes from a randomized human trial, not a testimonial.

The liver-fat trial

Retatrutide's glucagon activity points at the liver, and a separate Phase 2a trial in metabolic dysfunction-associated steatotic liver disease (MASLD) (Nature Medicine, 2024; 98 participants, 48 weeks) tested exactly that. Mean relative reduction in liver fat at 24 weeks reached −81.4% (8 mg) and −82.4% (12 mg) versus +0.3% for placebo, and normal liver fat (under 5%) was achieved by 79% (8 mg) and 86% (12 mg) of participants — versus 0% on placebo.

What the trials can't tell you (yet)

Now the discipline. These are Phase 2 results. What is still not established:

Long-term safety. The common adverse events were gastrointestinal (nausea, diarrhea, vomiting, constipation), mostly mild to moderate and dose-dependent, with dose-dependent heart-rate increases that peaked around 24 weeks. Longer, larger Phase 3 trials are what characterize the full safety picture.
Durability. We do not yet know how weight loss holds up over years, or after stopping.
Head-to-head superiority. The cross-trial comparisons to semaglutide and tirzepatide are suggestive, not proven.

Bottom line

Retatrutide earns its human-RCT badge — the strongest tier we award — because the claims above are anchored in published randomized trials. That is exactly why it belongs in a different conversation than the preclinical peptides. It is also still investigational and not FDA-approved, which means the honest verdict is: real data, real promise, unfinished story. For how our tiers work, see Evidence Tiers, Explained.

FAQ

Is retatrutide better than semaglutide or tirzepatide?: The Phase 2 weight-loss numbers are eye-catching — up to 24.2% at 48 weeks — but these come from separate trials with different populations and designs. Head-to-head randomized comparisons are what would settle it, and retatrutide is still in Phase 3 development. Treat cross-trial comparisons as suggestive, not decided.
Can I buy retatrutide?: Not legitimately. It is investigational and only available inside clinical trials. Anything sold as 'retatrutide' by a research-chemical or gray-market vendor is not the trial drug, is not quality-controlled, and is not authorized for human use.